Analyst Research Report Snapshot

Title:

PROSENSA - TRAGEDY AND HOPE

Price:

$10.00

Provider:

Edison Investment Research

Date:

15 Oct 2013

Pages:

2

Type:

AcrobatPDF

Companies referenced:

RNA.OQ

Available for Immediate Download
Summary:

Drisapersen’s Phase III in Duchenne muscular dystrophy (DMD) failed to show any efficacy. This was in contrast to earlier studies with encouraging results, including a Phase II open-label extension study in which the majority of 10 male patients stabilised over almost four years; they are now denied the drug until further analyses are available. Current Prosensa candidates based on newer molecular chemistries appear to have higher efficiency. It will be some time before anyone knows. GSK’s support may quietly wither, as its involvement rests on exercising its option to license a further product; abrupt cancellation looks unlikely.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.